Mr James Olding

James graduated from the University of Bristol in 2012, achieving Honours in Bachelors of Medicine & Surgery. He became a Member of the Royal College of Surgeons of England in 2015 (by examination), and is now a Senior Specialist Registrar in Oral & Maxillofacial Surgery in London, having graduated with Honours in Dentistry from King’s College London in 2021.

Following on from a longstanding interest in the treatment of diseases and trauma in the face, and in conjunction with training in facial surgery, James became fascinated with facial aesthetics, seeing non-surgical treatments as an essential component of managing patients’ cosmetic concerns. He rapidly moved to combine and integrate the different aspects of professional practice in facial aesthetics, drawing on surgical & non-surgical experience, as well as continued NHS practice and care of acutely ill patients with facial injuries.

In 2025, James was awarded Medical Aesthetics Practitioner of the Year at the Aesthetics Awards – awarded to the doctor, dentist or surgeon who has contributed most the aesthetics industry over the preceding 12 months. This award, as judged by peers in the industry, recognised James’ unique contribution at such an early stage to education, research, mentorship and clinical practice in aesthetics. James travels globally as an educator and thought leader as part of his role as a Faculty member for the Allergan Medical Institute, conducting work in 3 languages over multiple continents.

Having first established a successful private aesthetics practice, James was troubled by the lack of regulation in the sector, and decided to combine a campaign for higher standards with his passion for teaching through establishing Interface Aesthetics in 2019. Interface Aesthetics was awarded the Independent Training provider of the Year 2024 at the Aesthetics Awards, the ultimate accolade in education and training in aesthetics.
In addition to multiple publications in the area of facial trauma and aesthetics, James has presented nationally on the topic of safety and regulation in aesthetics. He is actively involved in campaigns to improve patient safety and increase regulation in injectables. He leads both clinical and academic research in the area, including as a Principal Investigator in a Phase 3 Randomised Controlled Trial in the use of botulinum toxin in the lower face.